洛铂与紫杉醇联合治疗晚期卵巢癌的临床观察

Efficacy Observation of Lobaplatin and Paclitaxel Therapy in Recurrent Advanced Ovarian Carcinoma

目的:观察洛铂与紫杉醇联合化疗治疗晚期卵巢癌的近期疗效及不良反应。方法:50例晚期卵巢癌(Ⅲ期或Ⅳ期)患者,其中26例患者采用洛铂+紫杉醇静脉化疗,其中洛铂30 mg/m2,d1天,紫杉醇135～175 mg/m2d1天。24例患者采用顺铂+紫杉醇静脉化疗,其中顺铂25 mg/m2,d1-3天,紫杉醇135～175 mg/m2d1天,2～4个疗程观察疗效。结果:26例洛铂组患者中,完全缓解7例,部分缓解8例,稳定9例,进展2例,有效率为57.7%。24例顺铂组患者中,完全缓解5例,部分缓解8例,稳定6例,进展5例,有效率为54.2%。主要毒副反应为骨髓抑制、骨骼酸痛、神经毒性和脱发。结论:洛铂联合紫杉醇治疗晚期卵巢癌疗效较好,毒副反应可以耐受。

Objective： To evaluate the effects of lobaplatin and paclitaxel on treating recurrent advanced ovarian carcinoma and their adverse reactions. Methods： A total of 50 patients （Ⅲ-Ⅳ） with recurrent advanced ovarian carcinoma were enrolled, including 26 cases of lobaplatin ＋ paclitaxel and 24 cases of cisplatin ＋ paclitaxel. Lobaplatin group（lobaplatin ＋ paclitaxel）： lobaplatin at a dose of 30 mg/m2 intravenous infusion on dl, and paclitaxel at a dose of 135- 175 mg/m2 intravenous infusion on day 1. Cisplatin group （cisplatin ＋ paclitaxel）： cisplatin at a dose of 24 mg/m2 intravenous infusion on dayl and paclitaxel at a dose of 135 - 175 mg/m2 intravenous infusion on dl. The efficacy was evaluated after 2-4 cycles. Results： Lobaplatin group： seven patients achieved complete response（CR）, eight pa- tients achieved partial response （PR）, nine patients achieved stable disease （SD） and two patients achieved progressed disease （PD）. The overall response rate （RR=CR＋PR） was 57.7 %. Cisplatin group： five patients achieved CR, eight patients achieved PR, six patients SD and five patients achieved PD. The overall response rate was 54.2 %. The major adverse effects were bone marrow depression, arthralgia, neurotoxicity and alopecia. Conclusion： Combined chemotherapy of lobaplatin and paclitaxel has a good anti-tumor activity and manage- able toxicity on recurrent advanced ovarian carcinoma patients.